Tag Archives: survival

High Mesothelin Rates May Be Good for Mesothelioma Patients

High Mesothelin Rates May Be Good for Mesothelioma Patients

Mesothelioma patients who have higher levels of mesothelin have better survival rates. This is the finding of a new study out of Australia. Mesothelin Proteins Mesothelin is a type of protein found in mesothelioma cancer cells. Mesothelioma is a rare type of cancer that develops from cells of the mesothelium, the lining that covers many of the internal organs of the body. It is caused by exposure to a toxic mineral called asbestos. Typically, mesothelioma requires aggressive treatments to stop the cancer from growing and spreading. Such treatments may include surgery, chemotherapy, radiation therapy, or some combination. Scientists aren’t sure what mesothelin does in cancer cells. But since mesothelin is only found in cancer cells, it could be a target … Continue reading High Mesothelin Rates May Be Good for Mesothelioma Patients »

Finding Patterns in Malignant Peritoneal Mesothelioma

Finding Patterns in Malignant Peritoneal Mesothelioma

Researchers from the United States looked at malignant peritoneal mesothelioma (MPM) data over eighteen years for patterns in incidence and survival. They found that the incidence of MPM cases was steady while survival rates have increased. More cancer-directed surgeries and better identification of cell types in MPM patients may be behind the improved survival rates. Second Most Common Site MPM is an aggressive disease caused by asbestos. The peritoneum is the space in your abdomen that contains the intestines, the stomach, and the liver. The abdomen (peritoneum) is the second most common site of mesothelioma after the pleural area (lungs and chest). Most doctors believe MPM is caused by the ingestion of asbestos fibers. Microscopic asbestos fibers become embedded in … Continue reading Finding Patterns in Malignant Peritoneal Mesothelioma »

Treatment Protocol of an 8-Year Survivor of Mesothelioma

Treatment Protocol of an 8-Year Survivor of Mesothelioma

A new article in Scholars Journal of Medical Case Reports outlines the treatment protocol of an 8-year survivor of mesothelioma. Malignant pleural mesothelioma is difficult to treat. This aggressive cancer is caused by asbestos exposure and is resistant to most standard cancer therapies, including radiotherapy. Many people diagnosed with mesothelioma die within a few months to a year. Paul Kraus is considered the longest documented survivor of mesothelioma in the world. He was diagnosed in 1997 and was given little hope of survival. Not willing to give up, he worked with a team of doctors to create his own tailored treatment protocol. This protocol included dramatic lifestyle changes, experimental therapies, dietary changes, mind-body medicine, and other modalities. Paul was fortunate. … Continue reading Treatment Protocol of an 8-Year Survivor of Mesothelioma »

Treatment Options Improving in the ‘New Era’ for Mesothelioma

Is Mesothelioma Still A Big Problem Worldwide?

Calling it a “new era” for malignant pleural mesothelioma, doctors from four of the nation’s top cancer centers have just published an update on treatment options for this rare disease.  The article was prepared by mesothelioma experts at MD Anderson Cancer Center in Texas, NYU Langone Medical Center, Memorial Sloan Kettering Cancer Center in New York and the Mayo Clinic in Minnesota.  The article in the Journal of Clinical Oncology highlights the recent FDA approvals of a new medical device and a new immunotherapy combination for pleural mesothelioma. The authors say these and other advances are “generating momentum” to find better mesothelioma therapies.  Tumor Treating Fields Changing the Game Pleural mesothelioma is fast-growing and difficult to treat. Mesothelioma rarely responds … Continue reading Treatment Options Improving in the ‘New Era’ for Mesothelioma »

Lung-Sparing Surgery and Mesothelioma Survival

lung-sparing surgery

Italian researchers say lung-sparing surgery can lead to long-term mesothelioma survival, even if surgeons take a more conservative approach.  Lung-sparing surgery for mesothelioma is also known as pleurectomy with decortication (P/D). P/D surgery is less extensive than the other main surgical approach for mesothelioma but it is also less risky. Now, doctors at Venice-Mestre Hospital say that, as long as it is performed early enough and combined with other treatments, lung-sparing surgery saves lives. Their report in the Journal of Thoracic Disease details the outcomes of 155 mesothelioma surgery patients tracked for a median of a year-and-a-half.  Extrapleural Pneumonectomy & Lung-Sparing Surgery Extrapleural pneumonectomy (EPP) is the most radical operation for pleural mesothelioma. In addition to removing the mesothelioma tumor … Continue reading Lung-Sparing Surgery and Mesothelioma Survival »

Second-Line Treatment with Ramucirumab Improves Mesothelioma Survival

second-line treatment with ramucirumab

New evidence suggests that second-line treatment with ramucirumab after first-line chemotherapy may lead to longer survival in people with pleural mesothelioma.  Researchers in Italy recently published results of a double-blind, placebo-controlled trial of the drug. Ramucirumab inhibits a protein mesothelioma tumors need to form new blood vessels.  The study included 161 pleural mesothelioma patients from across Italy. Researchers gave half of them second-line treatment with ramucirumab and another drug called gemcitabine. The other half had second-line treatment with gemcitabine alone.  Results showed the ramucirumab group lived more than six months longer than those who got only gemcitabine.  Few Options for Recurrent Mesothelioma Pleural mesothelioma is an aggressive cancer with few good treatment options. Most patients start with chemotherapy with Alimta. … Continue reading Second-Line Treatment with Ramucirumab Improves Mesothelioma Survival »

Academic Medical Centers Extend Peritoneal Mesothelioma Survival

academic medical centers

A new published study suggests that peritoneal mesothelioma patients treated at academic medical centers survive much longer than those who get their care at community hospitals. The study was conducted by Harvard Medical School researchers at Brigham and Women’s Hospital in Boston.  Peritoneal mesothelioma is a rare and aggressive cancer of abdominal membranes. There is no known cure. The new study compared outcomes and survival among more than 2,600 mesothelioma patients. Patients were treated at high-volume academic hospitals or community cancer centers.  The results suggest that academic medical centers consistently provide more advanced and potentially life-extending care for this complex cancer.  Experience is Critical for Mesothelioma Care Malignant mesothelioma is the name for cancers that occur on internal membranes. It … Continue reading Academic Medical Centers Extend Peritoneal Mesothelioma Survival »

Does Pleural Fluid Exposure Affect Mesothelioma Survival?

pleural fluid

A recent study found no link between mesothelioma survival and exposure to pleural fluid. But that does not necessarily mean the link doesn’t exist.  Pleural fluid is also called pleural effusions or “water on the lungs”. It is extra fluid that builds up around the lungs. It is common in people with heart failure, kidney or liver disease, pleural mesothelioma and some other kinds of cancer.  Pleural effusions are usually treated as an uncomfortable mesothelioma symptom. Draining the fluid can help patients breathe easier.  But researchers at Oxford University wondered whether the pleural fluid itself could shorten mesothelioma survival. In this study, the answer appears to be no. But the researchers warn this may not be the final word on … Continue reading Does Pleural Fluid Exposure Affect Mesothelioma Survival? »

Immunotherapy Treatment ONCOS-102: News Keeps Getting Better

Mesothelioma Response to Immunotherapy

The news just keeps getting better for the virus-based immunotherapy treatment ONCOS-102.  Norweigian drug maker Targovax recently released the final survival data from a two-year study of ONCOS-102 in people with malignant pleural mesothelioma.  Eighteen months into the study, it looked like some of the patients on the immunotherapy treatment would live longer than two years. Now that the ONCOS-102 study has passed the two year mark, researchers say median survival may be even longer.  Average survival is a year or less on standard mesothelioma therapies. This makes the news about ONCOS-102 especially exciting.  Standard of Care Versus Immunotherapy Treatment Malignant mesothelioma is an aggressive malignancy with a poor prognosis. Even patients in overall good health face a grim outlook. … Continue reading Immunotherapy Treatment ONCOS-102: News Keeps Getting Better »

Higher PD-L1 Protein May Predict Shorter Mesothelioma Survival

PD-L1 protein

Mesothelioma patients with higher levels of the PD-L1 protein in their tumor cells have worse overall survival compared to those with lower levels. But that may not be true for patients who have immunotherapy. That news comes from a new European study of more than 200 patients. PD-L1 and its partner protein PD-1 (found in immune system cells) are popular targets for new immunotherapy drugs. But the new study aimed to find out if they impact mesothelioma survival independently of immunotherapy. The team concluded the PD-L1 protein may shorten lifespan. PD-1 does not seem to have the same effect.  Pleural Mesothelioma and the PD-L1 Protein Pleural mesothelioma is an intractable cancer of the lung lining. It often leads to poor … Continue reading Higher PD-L1 Protein May Predict Shorter Mesothelioma Survival »